Cuprina Holdings has achieved a major milestone by securing FDA approval for a second carcass-feasting fly species, *Lucilia cuprina*, to be used in maggot wound therapy. This joins *Lucilia sericata*, already cleared in 2004, making Cuprina the sole company with dual FDA-approved maggot therapies. The move positions the Singapore-based firm to dominate the global MDT market, leveraging the international recognition of *L. cuprina* in regions like Australia and Asia. The company emphasizes that both species serve different markets but share the same therapeutic goals.

The FDA’s clearance of *L. cuprina*—an Australian sheep blowfly—expands clinicians’ options for maggot debridement therapy (MDT). While *L. sericata* remains the Western standard, *L. cuprina* offers familiarity in non-Western regions. This diversification could address gaps in wound care accessibility, particularly in areas where *L. sericata* is less established. Ronald Sherman, Cuprina’s Medical Director, called the approval a validation of MDT’s legitimacy, stating it strengthens the therapy’s scientific foundation. Critics note the lack of robust comparative data between the species, but proponents argue the redundancy reduces risk for patients and providers.

The approval underscores the growing role of biological therapies in modern medicine. For Cuprina, it’s a strategic win, but competitors may feel pressured to accelerate similar approvals. The FDA’s track record with maggot therapy since 2004 suggests a cautious but open regulatory stance. Clinicians now have more flexibility to tailor treatments, though cost and logistical barriers remain. Sherman’s endorsement highlights MDT’s niche but critical place in wound management. While *L. cuprina* doesn’t promise superior efficacy, its geographic versatility could accelerate adoption in underserved markets. This development reflects a broader shift toward unconventional therapies in mainstream healthcare.